Results 51 to 60 of about 7,946 (150)
Alcohol, Clinical and Experimental Research, Volume 50, Issue 7, July 2026.This cohort study examined whether GLP‐1 receptor agonist prescriptions are associated with alcohol use among NIH All of Us participants. Those with current GLP‐1RA prescriptions showed modestly lower AUDIT‐C scores compared to those with future prescriptions. GLP‐1RAs may reduce alcohol consumption by reducing drinking frequency.
Benjamin Tyndall +12 more
wiley +1 more source
Nicotine dependence and neuropsychotic effects of varenicline
Безопасность и риск фармакотерапии, 2018 Varenicline is a partial agonist of nicotinic acetylcholine receptors for the therapy of nicotine addiction. The efficacy and safety of the use of varenicline in the treatment of nicotine dependence have been demonstrated in clinical trial EAGLES.
T. M. Bukatina +4 more
doaj +1 more source
Frontiers in Behavioral Neuroscience, 2019 Nicotine is acknowledged as the key addictive compound of tobacco. Varenicline (Champix® or Chantix®), mainly acting as a partial agonist at the α4β2 nicotinic receptor, is an approved smoking cessation pharmacotherapy, although with efficacy limited to ...
Vernon Garcia-Rivas +13 more
doaj +1 more source
Addiction, Volume 121, Issue 7, Page 1876-1887, July 2026.Abstract Background and aims Tobacco‐cannabis co‐use is associated with increased psychosocial and health harms; however, the treatment literature assessing the impact of co‐use has been mixed and suffers from critical limitations. To date, no prospective studies have evaluated the degree to which cannabis co‐use affects tobacco cessation, nor are ...
Erin A. McClure +6 more
wiley +1 more source
Evaluation of the cardiovascular effects of varenicline in rats
Drug Design, Development and Therapy, 2015 Engin Burak Selçuk,1 Meltem Sungu,2 Hakan Parlakpinar,3 Necip Ermiş,4 Elif Taslıdere,5 Nigar Vardı,5 Murat Yalçinsoy,6 Mustafa Sagır,3 Alaaddin Polat,7 Mehmet Karatas,8 Burcu Kayhan-Tetik11Department of Family Medicine, 2Inonu University ...
Selçuk EB +10 more
doaj
Tobacco Induced Diseases, 2016 Introduction Varenicline is an effective smoking cessation medication. Some concern has been raised that its use may precipitate adverse cardiovascular events although no patho-physiological mechanism potentially underlying such an effect has been ...
Helge Haarmann +7 more
doaj +1 more source
Drug and Alcohol Review, Volume 45, Issue 5, July 2026.ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman +5 more
wiley +1 more source
Medical Journal of Australia, Volume 224, Issue 7, July 2026.ABSTRACT Introduction Lung cancer is the leading cause of cancer mortality in Australia. In July 2025, the Australian Government launched the National Lung Cancer Screening Program (the Program). The Program has been designed in accordance with the Medical Services Advisory Committee's recommendations.
Nicole M. Rankin +30 more
wiley +1 more source
Aggravation of Acute Adrenal Crisis Due to Varenicline in a Patient with Adrenal Insufficiency
Endocrinology Research and Practice, 2016 We present a male patient with the diagnosis of primary adrenal insufficiency. He had acute adrenal crisis while receiving varenicline treatment for smoking cessation. The patient was examined carefully for the potential cause of adrenal crisis.
Elif Turan +4 more
doaj +1 more source
Comprehensive Psychiatry, 2019 Background: The effects of the combination therapy of varenicline and bupropion in smoking cessation are still controversial. Methods: Databases including PubMed, EMBASE, Cochrane Library and Web of Science were scanned without time and language ...
Zhaoshuang Zhong +3 more
doaj +1 more source